The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
Abstract
BACKGROUND: Difelikefalin is a peripherally restricted and selective agonist of kappa opioid receptors that are considered to be important in modulating pruritus in conditions such as chronic kidney disease. METHODS: In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients undergoing hemodialysis who had moderate-to-severe pruritus to receive either intravenous difelikefalin (at a dose of 0.5 μg per kilogram of body weight) or placebo three times per week for 12 weeks. The primary outcome was the percentage of patients with an improvement (decrease) of at least 3 points from baseline at week 12 in the weekly mean score on the 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS; scores range from 0 to 10, with higher scores indicating greater itch intensity). The secondary outcomes included the change from baseline in itch-related quality-of-life measures, the percentage of patients with an improvement of at least 4 points in the WI-NRS score at week 12, and safety. RESULTS: A total of 378 patients underwent randomization. A total of 82 of 158 patients (51.9%) in the difelikefalin group had a decrease of at least 3 points in the WI-NRS score (primary outcome), as compared with 51 of 165 (30.9%) in the placebo group. The imputed percentage of patients with a decrease of at least 3 points in the WI-NRS score was 49.1% in the difelikefalin group, as compared with 27.9% in the placebo group (P<0.001). Difelikefalin also resulted in a significant improvement from baseline to week 12 in itch-related quality of life as measured by the 5-D itch scale and the Skindex-10 scale. The imputed percentage of patients with a decrease of at least 4 points in the WI-NRS score at week 12 was significantly greater in the difelikefalin group than in the placebo group (37.1% [observed data: 64 of 158 patients] vs. 17.9% [observed data: 35 of 165 patients], P<0.001). Diarrhea, dizziness, and vomiting were more common in the difelikefalin group than in the placebo group. CONCLUSIONS: Patients treated with difelikefalin had a significant reduction in itch intensity and improved itch-related quality of life as compared with those who received placebo. (Funded by Cara Therapeutics; KALM-1 ClinicalTrials.gov number, NCT03422653.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., & Rothman, R. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182234399 · Cited by 784
Pisoni, R. L., Wikstrom, B., Elder, S. J., Akizawa, T., Asano, Y., Keen, M. L., Saran, R., Mendelssohn, D. C., Young, E. W., & Port, F. K. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl461 · Cited by 641
Two New Rating Scales for Opiate Withdrawal
Handelsman, L., Cochrane, K. J., Aronson, M. J., Ness, R., Rubinstein, K. J., & Kanof, P. D. (1987) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998709001515 · Cited by 599
Phan, N., Blome, C., Fritz, F., Gerss, J., Reich, A., Ebata, T., Augustin, M., Szepietowski, J., & Ständer, S. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1246 · Cited by 575
Modification of Sample Size in Group Sequential Clinical Trials
Cui, L., Hung, H. M. J., & Wang, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00853.x · Cited by 574
The 5-D itch scale: a new measure of pruritus
Elman, S., Hynan, L. S., Gabriel, V., & Mayo, M. J. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09586.x · Cited by 540
Yosipovitch, G., Greaves, M. W., & Schmelz, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12570-6 · Cited by 388
Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients
Narita, I., Alchi, B., Omori, K., Sato, F., Ajiro, J., Saga, D., Kondo, D., Skatsume, M., Maruyama, S., Kazama, J. J., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000251 · Cited by 385
A Longitudinal Study of Uremic Pruritus in Hemodialysis Patients
Mathur, V. S., Lindberg, J., Germain, M., Block, G., Tumlin, J., Smith, M., Grewal, M., & McGuire, D. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00100110 · Cited by 324
Mettang, T., & Kremer, A. E. (2014) · Kidney International · doi:10.1038/ki.2013.454 · Cited by 286
Research works printed but not linked: 9
- 10.2215/CJN.03280317 · doi:10.2215/cjn.03280317
- 10.1111/hdi.12158 · doi:10.1111/hdi.12158
- 10.1093/ndt/gfi204 · doi:10.1093/ndt/gfi204
- Bigliardi PL Bigliardi-Qi M. Peripheral opioids. In: Carstens E Akiyama T eds. Itch: mechanisms and treatment. Boca Raton FL: CRC Press/Taylor & Francis 2014 (https://www.ncbi.nlm.nih.gov/books/NBK200922/).
- 10.1016/j.jpain.2015.01.341 · doi:10.1016/j.jpain.2015.01.341
- 10.1002/bimj.200390001 · doi:10.1002/bimj.200390001
- 10.1111/bjd.14464 · doi:10.1111/bjd.14464
- 10.1016/j.jpain.2015.01.340 · doi:10.1016/j.jpain.2015.01.340
- Butelman ER, Kreek MJ. Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front Pharmacol 2015;6:190-190.26441647
Cited by
Epidemiology of haemodialysis outcomes
Bello, A. K., Okpechi, I. G., Osman, M. A., Cho, Y., Htay, H., Jha, V., Wainstein, M., & Johnson, D. W. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00542-7 · Cited by 631
A basophil-neuronal axis promotes itch
Wang, F., Trier, A. M., Li, F., Kim, S., Chen, Z., Chai, J. N., Mack, M. R., Morrison, S. A., Hamilton, J. D., Baek, J., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.033 · Cited by 264
Itch: Pathogenesis and treatment
Sutaria, N., Adawi, W., Goldberg, R., Roh, Y. S., Choi, J., & Kwatra, S. G. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.07.078 · Cited by 130
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
Itch in Atopic Dermatitis – What Is New?
Legat, F. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644760 · Cited by 82
Metadata
- Authors
- Fishbane, S., Jamal, A., Munera, C., Wen, W., & Menzaghi, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2988468898
- Cited by
- 381
- References
- 20
- FWCI
- 28.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Cara Therapeutics, Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. https://app.cochat.ai/papers/10.1056/nejmoa1912770
- The paper
- Fishbane, S., Jamal, A., Munera, C., Wen, W., & Menzaghi, F. (2020). A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1912770
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.